🇺🇸 FDA
Pipeline program

GTI-2040

L01-1409

Phase 2 small_molecule completed

Quick answer

GTI-2040 for Carcinoma, Renal Cell is a Phase 2 program (small_molecule) at Aptose Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Aptose Biosciences
Indication
Carcinoma, Renal Cell
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials